Tobira Therapeutics Inc. (NASDAQ:TBRA)’s share price rose 3.5% on Friday . The company traded as high as $11.67 and last traded at $11.34, with a volume of 64,163 shares changing hands. The stock had previously closed at $10.96.

TBRA has been the topic of a number of research reports. Cantor Fitzgerald initiated coverage on Tobira Therapeutics in a report on Wednesday, July 6th. They issued a “buy” rating and a $27.00 target price on the stock. HC Wainwright reiterated a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, June 28th. Zacks Investment Research upgraded Tobira Therapeutics from a “hold” rating to a “strong-buy” rating and set a $9.25 target price on the stock in a report on Thursday, May 5th. Cowen and Company reiterated a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, May 10th. Finally, Leerink Swann reiterated a “buy” rating and issued a $18.00 target price on shares of Tobira Therapeutics in a report on Tuesday, May 10th. Five equities research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of $20.20.

The company has a 50-day moving average price of $11.72 and a 200-day moving average price of $8.80. The stock’s market cap is $211.67 million.

Tobira Therapeutics (NASDAQ:TBRA) last announced its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.12. Analysts expect that Tobira Therapeutics Inc. will post ($2.49) EPS for the current fiscal year.

In related news, major shareholder A/S Novo sold 59,067 shares of Tobira Therapeutics stock in a transaction dated Wednesday, July 13th. The stock was sold at an average price of $12.02, for a total value of $709,985.34. Following the completion of the sale, the insider now directly owns 1,914,541 shares in the company, valued at $23,012,782.82. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

An institutional investor recently bought a new position in Tobira Therapeutics stock. Marshall Wace LLP bought a new position in Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned approximately 0.57% of Tobira Therapeutics as of its most recent filing with the SEC.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.